Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401
1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902
Athyros, 2002, The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study, Curr Med Res Opin, 18, 220, 10.1185/030079902125000787
Serruys, 2002, Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomised controlled trial, JAMA, 287, 3215, 10.1001/jama.287.24.3215
Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001
Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615
2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X
2002, Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care, JAMA, 288, 2998, 10.1001/jama.288.23.2998
Woolf, 1999, Pathology of atherosclerosis
Stamler, 1986, Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?, JAMA, 256, 2823, 10.1001/jama.1986.03380200061022
Bloomfield Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604
Buchwald, 1990, Report of the program on the surgical control of the hyperlipidemias (POSCH): effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia, N Engl J Med, 323, 946, 10.1056/NEJM199010043231404
1998, Blood pressure, cholesterol, and stroke in eastern Asia, Lancet, 352, 1801, 10.1016/S0140-6736(98)03454-0
Crouse, 1998, HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data, Atherosclerosis, 138, 11, 10.1016/S0021-9150(98)00014-8
Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes, JAMA, 285, 1711, 10.1001/jama.285.13.1711
Martin, 1986, Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men, Lancet, 2, 933, 10.1016/S0140-6736(86)90597-0
Kannel, 1999, Importance of hypertension as a major risk factor in cardiovascular disease, 888
Stamler, 1992, The primary prevention of hypertension and the population blood pressure problem
Sever, 2001, Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial, J Hypertens, 6, 1139, 10.1097/00004872-200106000-00020
Hansson, 1992, Prospective Randomised Open Blinded Endpoint (PROBE) study: a novel design for intervention trials, Blood Pressure, 1, 113, 10.3109/08037059209077502
Freeman, 2001, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation, 103, 357, 10.1161/01.CIR.103.3.357
Bucher, 1999, Systematic review on the risk and benefit of different cholesterol-lowering interventions, Arterioscler Thromb Vasc Biol, 19, 187, 10.1161/01.ATV.19.2.187
Ramsay, 1999, Guidelines for management of hypertension: report of the third working party of the British Hypertension Society, 1999, J Hum Hypertens, 13, 569, 10.1038/sj.jhh.1000917
1998, Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments, J Hypertens, 16, 127
2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults, JAMA, 285, 2487
Ramsay, 1996, Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table, Lancet, 348, 387, 10.1016/S0140-6736(96)05516-X
Wood, 1998, Joint British recommendations on prevention of coronary heart disease in clinical practice, Heart, 80, S1
Glorioso, 1999, Effect of the MHG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia, Hypertension, 34, 1281, 10.1161/01.HYP.34.6.1281